- Home
- BIIB vs CHT Comparison
BIIB vs CHT Comparison
Compare BIIB & CHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CHT
- Stock Information
- Founded
- BIIB 1978
- CHT 1996
- Country
- BIIB United States
- CHT Taiwan
- Employees
- BIIB N/A
- CHT N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CHT Telecommunications Equipment
- Sector
- BIIB Health Care
- CHT Telecommunications
- Exchange
- BIIB Nasdaq
- CHT Nasdaq
- Market Cap
- BIIB 25.1B
- CHT 29.9B
- IPO Year
- BIIB 1991
- CHT 2003
- Fundamental
- Price
- BIIB $157.78
- CHT $38.42
- Analyst Decision
- BIIB Buy
- CHT
- Analyst Count
- BIIB 25
- CHT 0
- Target Price
- BIIB $258.57
- CHT N/A
- AVG Volume (30 Days)
- BIIB 1.5M
- CHT 132.2K
- Earning Date
- BIIB 10-30-2024
- CHT 01-28-2025
- Dividend Yield
- BIIB N/A
- CHT 3.83%
- EPS Growth
- BIIB 10.05
- CHT N/A
- EPS
- BIIB 11.06
- CHT 0.15
- Revenue
- BIIB $9,607,500,000.00
- CHT $7,132,621,133.00
- Revenue This Year
- BIIB N/A
- CHT $3.76
- Revenue Next Year
- BIIB N/A
- CHT $1.91
- P/E Ratio
- BIIB $14.26
- CHT $25.90
- Revenue Growth
- BIIB N/A
- CHT 2.58
- 52 Week Low
- BIIB $153.62
- CHT $35.92
- 52 Week High
- BIIB $268.30
- CHT $40.62
- Technical
- Relative Strength Index (RSI)
- BIIB 33.43
- CHT 54.60
- Support Level
- BIIB $158.44
- CHT $37.99
- Resistance Level
- BIIB $162.62
- CHT $38.78
- Average True Range (ATR)
- BIIB 3.19
- CHT 0.33
- MACD
- BIIB 0.90
- CHT 0.07
- Stochastic Oscillator
- BIIB 35.65
- CHT 73.36
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CHT Chunghwa Telecom Co. Ltd.
Chunghwa Telecom Co Ltd is Taiwan's integrated telecom operator, providing fixed-line, wireless, and Internet and data services. The company segment consists of Consumer Business, Enterprise Business, International Business, and Others. The company generates the majority of its revenue from the Consumer Business segment. The consumer Business segment generates revenue from Mobile services, Fixed-line services, Sales, and others.